Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic agent for keratoconjunctival disorder

A cornea and conjunctivitis technology, applied in sensory diseases, aerosol delivery, drug combination, etc., can solve the problem of no research on the pharmacological effects of eye diseases such as corneal and conjunctival lesions, and achieve the effect of improving the effect

Inactive Publication Date: 2008-07-30
SANTEN PHARMA CO LTD
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, there is no report on the pharmacological effects of the above-mentioned compounds on eye diseases such as keratoconjunctivopathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic agent for keratoconjunctival disorder
  • Therapeutic agent for keratoconjunctival disorder

Examples

Experimental program
Comparison scheme
Effect test

preparation example 2

[0054] 100ml

[0055] Compound B 100mg

[0056] Sodium chloride 800mg

[0057] Disodium hydrogen phosphate 100mg

[0058] Sodium dihydrogen phosphate amount

[0059] Appropriate amount of sterilized distilled water

[0060] By changing the amount of compound B added, the concentration can be adjusted to 0.01% (w / v), 0.3% (w / v), 0.5% (w / v), 1.5% (w / v), 3% (w / v ) eye drops.

preparation example 3

[0062] 100g

[0063] Compound A 0.3g

[0064] Liquid paraffin 10.0g

[0065] Appropriate amount of white petroleum jelly

[0066] Eye ointments with concentrations of 1% (w / w) and 3% (w / w) can be prepared by changing the amount of compound A added.

preparation example 4

[0068] 100g

[0069] Compound B 0.3g

[0070] Liquid paraffin 10.0g

[0071] Appropriate amount of white petroleum jelly

[0072] Eye ointments with concentrations of 1% (w / w) and 3% (w / w) can be prepared by changing the amount of compound B added.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An object of the present invention is to discover a new medicinal use of 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]p henylmethyl]thiazolidine-2,4-dione and N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine. Both of the compounds exert an excellent improving effect on corneal disorder models and is useful as a therapeutic agent for a keratoconjunctival disorder such as dry eyes, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defects, conjunctive epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis and filamentary keratitis.

Description

[0001] This application is a divisional application of an application with an application date of October 29, 2004, an application number of 200480031991.4 (international application number of PCT / JP2004 / 016460), and an invention title of "agent for treating keratoconjunctivopathy". technical field [0002] The present invention relates to containing 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4 -Diketone, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy] Phenyl]methyl]glycine or salts of the above compounds as active ingredients dry eye, corneal ulcer, keratitis, conjunctivitis, punctate superficial keratosis, corneal epithelial defect, conjunctival epithelial defect, keratoconjunctivitis sicca, upper A therapeutic agent for keratoconjunctivitis such as superior limbic keratoconjunctivitis and filamentous keratitis. Background technique [0003] The cornea is a transparent, avascular tissue with a diamete...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/517A61K31/421A61K9/06A61K9/08A61P27/02C07D263/32C07D417/12
Inventor 中村雅胤平井慎一郎
Owner SANTEN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com